A Phase I Study of Savolitinib in Recurrent, Progressive or Refractory Primary CNS Tumors
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Savolitinib (Primary)
- Indications CNS cancer; Glioma; Medulloblastoma
- Focus Adverse reactions
- 31 May 2019 Status changed from suspended to recruiting.
- 25 Jan 2019 Status changed from recruiting to suspended.
- 16 Nov 2018 Planned End Date changed from 31 Aug 2020 to 31 Dec 2020.